Frederik Giesel
Frederik Giesel co-developed FAPI PET imaging and now leads nuclear medicine in Düsseldorf.
Overview
Frederik Giesel is Director of Nuclear Medicine at University Hospital Düsseldorf, having previously worked at Heidelberg University Hospital within the NCT and DKFZ network. His specialisms are molecular imaging, FAPI PET and PSMA theranostics. He co-led the first-in-human FAPI PET studies in Heidelberg, and his Journal of Nuclear Medicine paper reported the biodistribution and preliminary dosimetry of two DOTA-containing FAP-targeting agents imaged with 68Ga-FAPI PET/CT. He continues to develop FAP-targeted imaging and therapy in Düsseldorf. His publications are listed on PubMed.
| Title | Journal | Year |
|---|---|---|
| 68Ga-FAPI PET/CT: biodistribution and preliminary dosimetry estimate of 2 DOTA-containing FAP-targeting agents | Journal of Nuclear Medicine | 2019 |
Similar pages
not linked directly; found by shared links- PersonUwe Haberkorn
Shares Journal of Nuclear Medicine, Heidelberg University Hospital / NCT / DKFZ, A university cyclotron network with shared regulatory files for new tracers, European Association of Nuclear Medicine.
- IdeaFAP theranostics as a pan-cancer stromal strategy
Shares A university cyclotron network with shared regulatory files for new tracers, FAP, FAPI PET.
- IdeaFAP-targeted radioligand therapy for sarcoma
Shares FAP, FAPI PET, Gallium-68.
- IdeaFAPI PET as the workup for MCED positives
- PersonClemens Kratochwil
Shares Journal of Nuclear Medicine, Heidelberg University Hospital / NCT / DKFZ, European Association of Nuclear Medicine.
- AgentGallium-68 FAPI-46
Shares FAP, FAPI PET, Gallium-68.
- CompanySOFIE Biosciences
Shares Heidelberg University Hospital / NCT / DKFZ, FAP, FAPI PET.
- OpportunityFAP imaging to stop futile pancreatic surgery
Shares FAP, FAPI PET, Gallium-68.